Quick Answer
REGENERON PHARMACEUTICALS, INC. reported Research And Development Expense of $5.85 billion for the year ending 2025.
- REGENERON PHARMACEUTICALS, INC. showed an increase of +14.0% in Research And Development Expense from 2024 to 2025.
- This data is from REGENERON PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 4, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2010: $117.47 million | Q2 2010: $124.53 million | Q3 2010: $122.04 million | Q1 2011: $129.39 million | Q2 2011: $143.15 million | Q3 2011: $127.92 million | Q1 2012: $138.86 million | Q2 2012: $147.37 million | Q3 2012: $158.30 million | Q1 2013: $180.30 million | Q2 2013: $187.46 million | Q3 2013: $224.05 million | Q1 2014: $287.38 million | Q2 2014: $294.50 million | Q3 2014: $337.73 million | Q1 2015: $343.11 million | Q2 2015: $390.33 million | Q3 2015: $425.92 million | Q1 2016: $470.11 million | Q2 2016: $559.93 million | Q3 2016: $543.05 million | Q1 2017: $507.44 million | Q2 2017: $509.98 million | Q3 2017: $529.75 million | Q1 2018: $498.60 million | Q2 2018: $529.30 million | Q3 2018: $557.00 million | Q1 2019: $486.10 million | Q2 2019: $885.50 million | Q3 2019: $526.00 million | Q1 2020: $583.90 million | Q2 2020: $722.00 million | Q3 2020: $684.60 million | Q1 2021: $742.90 million | Q2 2021: $714.20 million | Q3 2021: $665.40 million | Q1 2022: $843.80 million | Q2 2022: $794.30 million | Q3 2022: $911.30 million | Q1 2023: $1.10 billion | Q2 2023: $1.09 billion | Q3 2023: $1.08 billion | Q1 2024: $1.25 billion | Q2 2024: $1.20 billion | Q3 2024: $1.27 billion | Q1 2025: $1.33 billion | Q2 2025: $1.42 billion | Q3 2025: $1.48 billion.
- Over the full 18 years of available data (2008 to 2025), REGENERON PHARMACEUTICALS, INC.'s Research And Development Expense has grown by 2,028.1%.
- Historical annual values: Fiscal year 2025: $5.85 billion | Fiscal year 2024: $5.13 billion | Fiscal year 2023: $4.44 billion | Fiscal year 2022: $3.59 billion | Fiscal year 2021: $2.86 billion | Fiscal year 2020: $2.65 billion | Fiscal year 2019: $2.45 billion | Fiscal year 2018: $1.47 billion | Fiscal year 2017: $2.08 billion | Fiscal year 2016: $2.05 billion | Fiscal year 2015: $1.62 billion | Fiscal year 2014: $1.27 billion | Fiscal year 2013: $859.95 million | Fiscal year 2012: $625.55 million | Fiscal year 2011: $529.51 million | Fiscal year 2010: $489.25 million | Fiscal year 2009: $398.76 million | Fiscal year 2008: $274.90 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: